BioProject

Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. More...

Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. It is well recognize that clinical and molecular heterogeneity of TNBC is driven in part by mRNA and lncRNAs. To stratify TNBCs, we profiled mRNAs and lncRNA in 158 adjuvant TNBC tumors using an Affymetrix microarray platform. Lehmann clustering analysis allowed us to identify TNBC subtypes featuring unique lncRNA expression patterns, disease free and overall survival rates and particular gene ontology enrichments (performed with GSEA algorithm). Overall design: Breast cancer tumors were collected from the archives of the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan (INT) after a carefully histopathological review by two training pathologist, according to the following criteria: adjuvant therapy and collection of the surgical sample without any treatment. We obtain triple negative tumors (ER-, PR- and Her2-) and tumors from other immunophenotype (ER+, PR+ or/and Her2+) by microdissection of tumoral cells for RNA extraction and hybridization on Affymetrix microarrays. Less...